CD19 and graft versus host disease: The development of a safe and low-risk allo-HSCT approach such as the TCRαβ/CD19-depleted platform and the improved knowledge chemoterapic agents such as Treo can guarantee an effective therapeutic approach in IEI with reduced burden of toxicity and GvHD.